# Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

> **NCT03479372** · PHASE1,PHASE2 · COMPLETED · sponsor: **PanOptica, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** PAN-90806 Ophthalmic Suspension

## Key facts

- **NCT ID:** NCT03479372
- **Lead sponsor:** PanOptica, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2019-05-27
- **Final completion:** 2019-06-27
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03479372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03479372, "Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03479372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*